Literature DB >> 19105708

Cancer vaccines: will we ever learn?

Robert S Johnson1, Anthony I Walker, Stephen J Ward.   

Abstract

Scientists and clinicians engaged in developing therapeutic cancer vaccines cannot be anything other than troubled by the sheer number of Phase III clinical trial failures in the field. Are we inveterate optimists or do we have reason for continuing to plough our lonely furrow? In this perspective article, we answer why Phase III failures have been to the fore and highlight why the field should be optimistic given the knowledge gained from these pioneering studies and our improved understanding of how the immune system interacts with cancer.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19105708     DOI： 10.1586/14737140.9.1.67

Source DB:  PubMed          Journal:  Expert Rev Anticancer Ther        ISSN： 1473-7140            Impact factor:   4.512


  6 in total

Review 1.  Beyond cancer vaccines: a reason for future optimism with immunomodulatory therapy.

Authors:  Michael Postow; Margaret K Callahan; Jedd D Wolchok
Journal:  Cancer J       Date:  2011 Sep-Oct       Impact factor: 3.360

Review 2.  Immunologic privilege in the central nervous system and the blood-brain barrier.

Authors:  Leslie L Muldoon; Jorge I Alvarez; David J Begley; Ruben J Boado; Gregory J Del Zoppo; Nancy D Doolittle; Britta Engelhardt; John M Hallenbeck; Russell R Lonser; John R Ohlfest; Alexandre Prat; Maurizio Scarpa; Richard J Smeyne; Lester R Drewes; Edward A Neuwelt
Journal:  J Cereb Blood Flow Metab       Date:  2012-10-17       Impact factor: 6.200

3.  Superior efficacy of tumor cell vaccines grown in physiologic oxygen.

Authors:  Michael R Olin; Brian M Andersen; David M Zellmer; Patrick T Grogan; Flavia E Popescu; Zhengming Xiong; Colleen L Forster; Charlie Seiler; Karen S SantaCruz; Wei Chen; Bruce R Blazar; John R Ohlfest
Journal:  Clin Cancer Res       Date:  2010-09-21       Impact factor: 12.531

4.  Targeting localized immune suppression within the tumor through repeat cycles of immune cell-oncolytic virus combination therapy.

Authors:  Stephen H Thorne; Wenchun Liang; Padma Sampath; Tobi Schmidt; Rachel Sikorski; Andreas Beilhack; Christopher H Contag
Journal:  Mol Ther       Date:  2010-07-06       Impact factor: 11.454

5.  Detecting T-cell reactivity to whole cell vaccines: Proof of concept analysis of T-cell response to K562 cell antigens in CML patients.

Authors:  Ana Brusic; Ursula Hainz; Martha Wadleigh; Donna Neuberg; Mei Su; Christine M Canning; Daniel J Deangelo; Richard M Stone; Jeng-Shin Lee; Richard C Mulligan; Jerome Ritz; Glenn Dranoff; Tetsuro Sasada; Catherine J Wu
Journal:  Oncoimmunology       Date:  2012-10-01       Impact factor: 8.110

6.  Therapeutic vaccination against autologous cancer stem cells with mRNA-transfected dendritic cells in patients with glioblastoma.

Authors:  Einar Osland Vik-Mo; Marta Nyakas; Birthe Viftrup Mikkelsen; Morten Carstens Moe; Paulina Due-Tønnesen; Else Marit Inderberg Suso; Stein Sæbøe-Larssen; Cecilie Sandberg; Jan E Brinchmann; Eirik Helseth; Anne-Marie Rasmussen; Knut Lote; Steinar Aamdal; Gustav Gaudernack; Gunnar Kvalheim; Iver A Langmoen
Journal:  Cancer Immunol Immunother       Date:  2013-07-02       Impact factor: 6.968
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.